Multiple myeloma (MM) is a malignant plasma cell disorder ... and following frontline therapy in nontransplant patients. CR: Complete response; EFS: Event-free survival; n: Number of patients ...

The treatment landscape for multiple ... myeloma who had a median of six prior lines of therapy. The results so far are ...

relapsed myeloma and post-transplant maintenance. Lenalidomide is generally well tolerated, with primary AEs being myelosuppression and thromboembolic complications, which are manageable with dose ...

Johnson & Johnson is in pole position to bring a drug targeting GPRC5D to market as a new therapeutic approach to multiple ... (VGPR) with the lower dose, along with 33.6% complete responses (CR ...

Regeneron Pharmaceuticals has reported encouraging results from the Phase I/II LINKER-MM1 clinical trial of its investigational bispecific antibody, linvoseltamab, in patients with relapsed ...